Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice.
MouseChemical/toxinBALB/cMalen = 24 BALB/c mice randomised across four armsProphylactic pretreatment before doxorubicin administration
Model: Doxorubicin-induced acute cardiotoxicity, assessed five days after doxorubicin injection
Relative to doxorubicin-treated mice without RRx-001, RRx-001 pretreatment improved left ventricular systolic pressure by 27%, dP/dt by 25%, stroke volume by 52%, ejection fraction by 20%, stroke work by 62.5%, heart rate by 18%, cardiac output by 57% and mean arterial pressure by 30%, and reduced…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.